☆ 4.6 Article

Immune-related thyroid dysfunctions during anti PD-1/PD-L1 inhibitors: new evidence from a single centre experience

CLINICAL AND EXPERIMENTAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Immune Checkpoint Inhibitor-induced Thyroid Disorders: A Single Center Experience

Armando Patrizio et al.

Summary: This study evaluated the development of thyroid dysfunction in cancer patients treated with immune checkpoint inhibitors. The results showed that all patients eventually developed persistent hypothyroidism, regardless of the initial presentation. Changes in thyroid volume could be helpful in the diagnostic work-up.

CURRENT PHARMACEUTICAL DESIGN (2023)

Add to Collection

Review Oncology

Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis

Yee-Ming Melody Cheung et al.

Summary: The development of immune-related thyroid dysfunction during immune checkpoint inhibitor therapy is associated with improved overall survival and progression free survival for cancer patients. This suggests that thyroid immune-related adverse events can be used as a surrogate marker for clinical response to ICIs.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Article Endocrinology & Metabolism

Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events

Christopher A. Muir et al.

Summary: This study found that positivity for TPOAb and TgAb at baseline was more prevalent in patients who developed thyroid irAEs, particularly overt thyrotoxicosis. During ICI treatment, significant increases in TgAb and TPOAb titers were associated with overt thyrotoxicosis. TPOAb and TgAb positivity or increases during ICI treatment may be a useful biomarker to identify patients at increased risk of thyroid irAEs.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Add to Collection

Article Endocrinology & Metabolism

Immune checkpoint inhibitor-related thyroid dysfunction

Shintaro Iwama et al.

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Add to Collection

Article Endocrinology & Metabolism

Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis

Tina Mosaferi et al.

Summary: Patients with ICI-associated hypothyroidism have different thyroid hormone dosing requirements than patients with HT. Based on our findings and prior reports, we recommend that in patients with ICI-associated thyroiditis LT4 therapy be started at an initial weight-based dose of 1.45 mcg/[kg center dot day] once serum free thyroxine levels fall below the reference range.

THYROID (2022)

Add to Collection

Review Endocrinology & Metabolism

Immune Related Adverse Events of the Thyroid - A Narrative Review

Christopher A. Muir et al.

Summary: The translated article introduces immune checkpoints, immune checkpoint inhibitors, and the association of thyroid dysfunction with immune-related adverse events (irAEs). Thyroid irAEs may be associated with increased immune toxicity in other organ systems and longer progression-free and overall survival.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline

Eystein S. Husebye et al.

Summary: This guideline provides evidence-based recommendations for the treatment and follow-up of patients with immune checkpoint inhibitor (ICI)-induced endocrine side-effects. A systematic approach to diagnosis, treatment, and follow-up is needed, including baseline tests of endocrine function before each treatment cycle. There is no clear evidence for the benefit of high-dose glucocorticoids in treating endocrine toxicities, with the possible exceptions of severe thyroid eye disease and hypophysitis affecting the visual apparatus. Most endocrine dysfunctions appear to be permanent regardless of ICI discontinuation.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2022)

Add to Collection

Article Oncology

The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study

N. Izawa et al.

Summary: The clinical utility of comprehensive measurement of autoimmune disease-related antibodies (Abs) before immune checkpoint inhibitor (ICI) therapy is limited for predicting immune-related adverse events (irAEs). However, Tg and TPO Abs are risk factors for the development of ICI-induced thyroid dysfunction.

ESMO OPEN (2022)

Add to Collection

Article Oncology

Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors

Joana Lima Ferreira et al.

Summary: Immune-checkpoint inhibitors can lead to thyroid function abnormalities, including primary and central hypothyroidism, which may be predictive of improved clinical outcomes and response to ICI treatment across different types of neoplasms.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Endocrinology & Metabolism

Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy

L. Brilli et al.

Summary: This study aimed to identify predictive factors for the development of thyroid dysfunction during immunotherapy in patients with metastatic or unresectable advanced cancers treated with immune checkpoint inhibitors. Results showed that pre-treatment serum TSH and ATAbs levels may help to identify patients at high risk for primary thyroid dysfunction. This suggests guidance for appropriate screening and management of thyroid dysfunctions in patients undergoing ICIs treatment.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2021)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Are radiologists ready to evaluate true response to immunotherapy?

Inci Kizildag Yirgin et al.

Summary: Standardized response criteria are crucial in evaluating radiological imaging for cancer management, with immunotherapy showing promise in treating chemotherapy-resistant cancers using immune checkpoint inhibitors. Further research is needed to validate the latest immune-RECIST criteria in response assessment and to address challenges in tumor evaluation and management faced by radiologists.

INSIGHTS INTO IMAGING (2021)

Add to Collection

Article Endocrinology & Metabolism

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors

Jee Hee Yoon et al.

Summary: Thyroid immune-related adverse events are common in cancer patients treated with PD-1/PD-L1 inhibitors, with the majority of patients being able to recover normal thyroid function. However, some patients may progress to overt hypothyroidism and require thyroid hormone replacement therapy. Risk factors for developing overt hypothyroidism include higher baseline thyroid stimulating hormone levels and longer duration of therapy.

ENDOCRINOLOGY AND METABOLISM (2021)

Add to Collection

Article Oncology

Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies

Alexandra Frelau et al.

Summary: This study found that thyroid dysfunctions induced by anti-PD-1 were not an independent predictive factor for progression-free survival in metastatic melanoma patients, but seemed to be associated with a better treatment response and increased overall survival.

MELANOMA RESEARCH (2021)

Add to Collection

Review Endocrinology & Metabolism

Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers

Anupam Kotwal et al.

Summary: Studies have shown a link between immune-related adverse events induced by ICIs and improved survival in cancer patients, with thyroid irAEs being most strongly associated with improved outcomes.

CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2021)

Add to Collection

Review Endocrinology & Metabolism

New insight in endocrine-related adverse events associated to immune checkpoint blockade

Giusy Elia et al.

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2020)

Add to Collection

Article Oncology

Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study

Norio Okada et al.

BRITISH JOURNAL OF CANCER (2020)

Add to Collection

Article Endocrinology & Metabolism

PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients

Anupam Kotwal et al.

THYROID (2020)

Add to Collection

Article Oncology

French Endocrine Society Guidance on endocrine side effects of immunotherapy

F. Castinetti et al.

ENDOCRINE-RELATED CANCER (2019)

Add to Collection

Article Endocrinology & Metabolism

BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION

Rena M. Pollack et al.

ENDOCRINE PRACTICE (2019)

Add to Collection

Article Medicine, General & Internal

Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients

Pauline Campredon et al.

PRESSE MEDICALE (2019)

Add to Collection

Article Endocrinology & Metabolism

Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes

Inmaculada Peiro et al.

ENDOCRINE (2019)

Add to Collection

Review Oncology

Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors: Practical Recommendations for Diagnosis and Clinical Management

Romualdo Barroso-Sousa et al.

CANCER (2018)

Add to Collection

Article Oncology

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Shiro Kimbara et al.

CANCER SCIENCE (2018)

Add to Collection

Review Oncology

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Lesley Seymour et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy

Hyunju Lee et al.

CANCER IMMUNOLOGY RESEARCH (2017)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.